MERCK & COMPANY INC

NYSE: MRK (Merck & Company, Inc.)

最近更新时间: 27 Oct, 12:27AM

87.49

0.31 (0.36%)

  • 1天 0.36%
  • 5天 0.53%
  • 1月 -1.48%
  • 6月 5.61%
  • 今年至今天 -11.78%
  • 1年 -14.12%
  • 5年 13.73%
前收盘价格 87.18
收盘价格 87.33
成交量 5,503,322
平均成交量 (3个月) 12,252,287
市值 218,531,053,568
市盈率 (P/E TTM) 13.48
预期市盈率 (P/E Forward) 9.13
价格/销量 (P/S) 3.56
股市价格/股市净资产 (P/B) 4.56
52周波幅
73.31 (-16%) — 105.11 (20%)
利润日期 30 Oct 2025
股息率 (DY TTM) 1.85%
营业毛利率 27.27%
营业利益率 (TTM) 40.06%
稀释每股收益 (EPS TTM) 6.88
季度收入增长率 (YOY) -1.60%
季度盈利增长率 (YOY) 6.70%
总债务/股东权益 (D/E MRQ) 71.99%
流动比率 (MRQ) 1.41
营业现金流 (OCF TTM) 20.88 B
杠杆自由现金流 (LFCF TTM) 17.12 B
资产报酬率 (ROA TTM) 13.81%
股东权益报酬率 (ROE TTM) 39.29%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看跌
Drug Manufacturers - General (全球的) 看涨 看跌
股票 Merck & Company, Inc. 看涨 看跌

AIStockmoo 评分

0.4
分析师共识 3.0
内部交易活动 NA
价格波动 1.0
技术平均移动指标 -1.0
技术振荡指标 -1.5
平均 0.38

相关股票

股票 市值 DY P/E（TTM） P/B
MRK 219 B 1.85% 13.48 4.56
NVS 255 B 3.27% 19.16 6.04
NVO 236 B 2.08% 13.65 8.32
LLY 787 B 0.32% 43.02 40.22
JNJ 450 B 1.33% 18.04 5.71
ABBV 403 B 1.44% 108.67 50.46

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
内部持股比例 0.06%
机构持股比例 80.62%
52周波幅
73.31 (-16%) — 105.11 (20%)
目标价格波幅
90.00 (2%) — 100.00 (14%)
高 100.00 (Morgan Stanley, 14.30%) 保留
中 95.00 (8.58%)
低 90.00 (Berenberg, 2.87%) 保留
平均值 95.00 (8.58%)
总计 3 保留
平均价格@调整类型 83.11
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 03 Nov 2025 100.00 (14.30%) 保留 82.49
Citigroup 13 Oct 2025 95.00 (8.58%) 保留 85.70
Berenberg 17 Sep 2025 90.00 (2.87%) 保留 81.14

该时间范围内无数据。

  • 3M
日期 类型 细节
30 Oct 2025 公告 Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
30 Oct 2025 CNBC Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
29 Oct 2025 公告 Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
29 Oct 2025 公告 European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
28 Oct 2025 公告 Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
28 Oct 2025 公告 Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
27 Oct 2025 公告 U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study
23 Oct 2025 公告 Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025
23 Oct 2025 公告 FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer
23 Oct 2025 公告 eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience
21 Oct 2025 公告 Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
20 Oct 2025 公告 Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia
20 Oct 2025 公告 KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
19 Oct 2025 公告 Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
18 Oct 2025 公告 KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
18 Oct 2025 公告 KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
18 Oct 2025 公告 KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
16 Oct 2025 公告 Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
15 Oct 2025 公告 Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
09 Oct 2025 公告 Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
09 Oct 2025 公告 Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
07 Oct 2025 公告 Merck Completes Acquisition of Verona Pharma
06 Oct 2025 公告 Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
01 Oct 2025 公告 Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
30 Sep 2025 公告 WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
19 Sep 2025 公告 Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
19 Sep 2025 CNBC RFK Jr.'s vaccine panel postpones vote on whether to delay babies' first hepatitis B shot
19 Sep 2025 公告 Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
19 Sep 2025 公告 FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
17 Sep 2025 公告 Advancing Cancer Research Brings New Hope for Patients Worldwide
15 Sep 2025 公告 Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab
11 Sep 2025 公告 CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease
07 Sep 2025 公告 Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
02 Sep 2025 公告 Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
02 Sep 2025 公告 Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
30 Aug 2025 公告 Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
28 Aug 2025 公告 Merck to Participate in the 2025 Wells Fargo Healthcare Conference
27 Aug 2025 公告 HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
25 Aug 2025 公告 Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
19 Aug 2025 公告 Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds
18 Aug 2025 公告 Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
12 Aug 2025 公告 KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
04 Aug 2025 公告 Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
显示更多
股息率 (DY TTM) 1.85%
5年平均股息收益率 2.96%
股息支付比率 45.93%
预计下次股息支付 Jan 2026
除息日 公告日期 支付日期 详情
17 Mar 2025 28 Jan 2025 07 Apr 2025 0.81 现金
16 Dec 2024 19 Nov 2024 08 Jan 2025 0.81 现金
16 Sep 2024 23 Jul 2024 07 Oct 2024 0.77 现金
17 Jun 2024 28 May 2024 08 Jul 2024 0.77 现金
14 Mar 2024 23 Jan 2024 05 Apr 2024 0.77 现金
14 Dec 2023 28 Nov 2023 08 Jan 2024 0.77 现金
14 Sep 2023 25 Jul 2023 06 Oct 2023 0.73 现金
14 Jun 2023 23 May 2023 10 Jul 2023 0.73 现金
14 Mar 2023 24 Jan 2023 10 Apr 2023 0.73 现金
14 Dec 2022 29 Nov 2022 09 Jan 2023 0.73 现金
14 Sep 2022 26 Jul 2022 07 Oct 2022 0.69 现金
14 Jun 2022 24 May 2022 08 Jul 2022 0.69 现金
14 Mar 2022 25 Jan 2022 07 Apr 2022 0.69 现金
14 Dec 2021 30 Nov 2021 07 Jan 2022 0.69 现金
14 Sep 2021 27 Jul 2021 07 Oct 2021 0.65 现金
14 Jun 2021 25 May 2021 07 Jul 2021 0.65 现金
12 Mar 2021 26 Jan 2021 07 Apr 2021 0.65 现金
14 Dec 2020 17 Nov 2020 08 Jan 2021 0.65 现金
14 Sep 2020 28 Jul 2020 07 Oct 2020 0.61 现金
12 Jun 2020 26 May 2020 07 Jul 2020 0.61 现金
13 Mar 2020 28 Jan 2020 07 Apr 2020 0.61 现金
13 Dec 2019 20 Nov 2019 08 Jan 2020 0.61 现金
13 Sep 2019 24 Jul 2019 07 Oct 2019 0.55 现金
14 Jun 2019 29 May 2019 08 Jul 2019 0.55 现金
14 Mar 2019 30 Jan 2019 05 Apr 2019 0.55 现金
14 Dec 2018 26 Oct 2018 08 Jan 2019 0.55 现金
14 Sep 2018 25 Jul 2018 05 Oct 2018 0.48 现金
14 Jun 2018 23 May 2018 09 Jul 2018 0.48 现金
14 Mar 2018 24 Jan 2018 06 Apr 2018 0.48 现金
14 Dec 2017 29 Nov 2017 08 Jan 2018 0.48 现金
14 Sep 2017 26 Jul 2017 06 Oct 2017 0.47 现金
13 Jun 2017 24 May 2017 10 Jul 2017 0.47 现金
13 Mar 2017 28 Feb 2017 07 Apr 2017 0.47 现金
13 Dec 2016 22 Nov 2016 09 Jan 2017 0.47 现金
13 Sep 2016 26 Jul 2016 07 Oct 2016 0.46 现金
13 Jun 2016 25 May 2016 08 Jul 2016 0.46 现金
11 Mar 2016 24 Feb 2016 07 Apr 2016 0.46 现金
11 Dec 2015 24 Nov 2015 08 Jan 2016 0.46 现金
11 Sep 2015 22 Jul 2015 07 Oct 2015 0.45 现金
11 Jun 2015 26 May 2015 08 Jul 2015 0.45 现金
12 Mar 2015 24 Feb 2015 08 Apr 2015 0.45 现金
11 Dec 2014 25 Nov 2014 08 Jan 2015 0.45 现金
11 Sep 2014 23 Jul 2014 07 Oct 2014 0.44 现金
12 Jun 2014 27 May 2014 08 Jul 2014 0.44 现金
13 Mar 2014 25 Feb 2014 07 Apr 2014 0.44 现金
12 Dec 2013 26 Nov 2013 08 Jan 2014 0.44 现金
12 Sep 2013 23 Jul 2013 07 Oct 2013 0.43 现金
13 Jun 2013 28 May 2013 08 Jul 2013 0.43 现金
13 Mar 2013 26 Feb 2013 05 Apr 2013 0.43 现金
13 Dec 2012 27 Nov 2012 08 Jan 2013 0.43 现金
13 Sep 2012 24 Jul 2012 05 Oct 2012 0.42 现金
13 Jun 2012 22 May 2012 09 Jul 2012 0.42 现金
13 Mar 2012 28 Feb 2012 06 Apr 2012 0.42 现金
13 Dec 2011 10 Nov 2011 09 Jan 2012 0.42 现金
13 Sep 2011 26 Jul 2011 07 Oct 2011 0.38 现金
13 Jun 2011 24 May 2011 08 Jul 2011 0.38 现金
11 Mar 2011 22 Feb 2011 07 Apr 2011 0.38 现金
13 Dec 2010 23 Nov 2010 07 Jan 2011 0.38 现金
13 Sep 2010 27 Jul 2010 07 Oct 2010 0.38 现金
11 Jun 2010 26 May 2010 08 Jul 2010 0.38 现金
11 Mar 2010 23 Feb 2010 07 Apr 2010 0.38 现金
11 Dec 2009 24 Nov 2009 08 Jan 2010 0.38 现金
02 Sep 2009 28 Jul 2009 01 Oct 2009 0.38 现金
04 Jun 2009 27 May 2009 01 Jul 2009 0.38 现金
04 Mar 2009 24 Feb 2009 01 Apr 2009 0.38 现金
03 Dec 2008 25 Nov 2008 02 Jan 2009 0.38 现金
03 Sep 2008 22 Jul 2008 01 Oct 2008 0.38 现金
04 Jun 2008 27 May 2008 01 Jul 2008 0.38 现金
05 Mar 2008 26 Feb 2008 01 Apr 2008 0.38 现金
05 Dec 2007 27 Nov 2007 02 Jan 2008 0.38 现金
05 Sep 2007 24 Jul 2007 01 Oct 2007 0.38 现金
06 Jun 2007 22 May 2007 02 Jul 2007 0.38 现金
07 Mar 2007 27 Feb 2007 02 Apr 2007 0.38 现金
06 Dec 2006 28 Nov 2006 02 Jan 2007 0.38 现金
30 Aug 2006 25 Jul 2006 02 Oct 2006 0.38 现金
31 May 2006 23 May 2006 03 Jul 2006 0.38 现金
31 Aug 2005 26 Jul 2005 03 Oct 2005 0.38 现金
01 Jun 2005 24 May 2005 01 Jul 2005 0.38 现金
02 Mar 2005 22 Feb 2005 01 Apr 2005 0.38 现金
01 Dec 2004 23 Nov 2004 03 Jan 2005 0.38 现金
01 Sep 2004 27 Jul 2004 01 Oct 2004 0.38 现金
02 Jun 2004 25 May 2004 01 Jul 2004 0.37 现金
03 Mar 2004 24 Feb 2004 01 Apr 2004 0.37 现金
03 Dec 2003 25 Nov 2003 02 Jan 2004 0.37 现金
03 Sep 2003 22 Jul 2003 01 Oct 2003 0.37 现金
04 Jun 2003 27 May 2003 01 Jul 2003 0.36 现金
05 Mar 2003 25 Feb 2003 01 Apr 2003 0.36 现金
04 Dec 2002 26 Nov 2002 02 Jan 2003 0.36 现金
04 Sep 2002 23 Jul 2002 01 Oct 2002 0.36 现金
05 Jun 2002 28 May 2002 01 Jul 2002 0.35 现金
06 Mar 2002 26 Feb 2002 01 Apr 2002 0.35 现金
05 Dec 2001 27 Nov 2001 02 Jan 2002 0.35 现金
30 Aug 2001 24 Jul 2001 01 Oct 2001 0.35 现金
31 May 2001 22 May 2001 02 Jul 2001 0.34 现金
07 Mar 2001 27 Feb 2001 02 Apr 2001 0.34 现金
06 Dec 2000 28 Nov 2000 02 Jan 2001 0.34 现金
30 Aug 2000 25 Jul 2000 02 Oct 2000 0.34 现金
31 May 2000 22 May 2000 03 Jul 2000 0.29 现金
01 Mar 2000 22 Feb 2000 03 Apr 2000 0.29 现金
01 Dec 1999 23 Nov 1999 03 Jan 2000 0.29 现金
01 Sep 1999 27 Jul 1999 01 Oct 1999 0.29 现金
02 Jun 1999 25 May 1999 01 Jul 1999 0.27 现金
03 Mar 1999 23 Feb 1999 01 Apr 1999 0.27 现金
02 Dec 1998 24 Nov 1998 04 Jan 1999 0.54 现金
02 Sep 1998 28 Jul 1998 01 Oct 1998 0.54 现金
03 Jun 1998 26 May 1998 01 Jul 1998 0.45 现金
04 Mar 1998 24 Feb 1998 01 Apr 1998 0.45 现金
03 Dec 1997 25 Nov 1997 02 Jan 1998 0.45 现金
03 Sep 1997 22 Jul 1997 01 Oct 1997 0.45 现金
05 Jun 1997 28 May 1997 01 Jul 1997 0.42 现金
05 Mar 1997 25 Feb 1997 01 Apr 1997 0.42 现金
05 Dec 1996 26 Nov 1996 02 Jan 1997 0.4 现金
04 Sep 1996 23 Jul 1996 01 Oct 1996 0.4 现金
06 Jun 1996 29 May 1996 01 Jul 1996 0.34 现金
06 Mar 1996 27 Feb 1996 01 Apr 1996 0.34 现金
06 Dec 1995 28 Nov 1995 02 Jan 1996 0.34 现金
05 Sep 1995 25 Jul 1995 02 Oct 1995 0.34 现金
02 Jun 1995 23 May 1995 03 Jul 1995 0.3 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.62 2 1.85
2024 3.08 4 3.10
2023 2.92 4 2.68
2022 2.76 4 2.49
2021 2.60 4 3.39
2020 2.44 4 3.13
2019 2.20 4 2.54
2018 1.92 4 2.63
2017 1.88 4 3.50
2016 1.84 4 3.28
2015 1.80 4 3.57
2014 1.76 4 3.25
2013 1.72 4 3.60
2012 1.68 4 4.30
2011 1.52 4 4.23
2010 1.52 4 4.42
2009 1.52 4 4.36
2008 1.52 4 5.24
2007 1.52 4 2.74
2006 0.760 2 1.83
2005 1.52 4 5.01
2004 1.49 4 4.86
2003 1.45 4 3.29
2002 1.41 4 2.61
2001 1.37 4 2.44
2000 1.21 4 1.35
1999 1.37 4 2.14
1998 1.89 4 2.69
1997 1.69 4 3.34
1996 1.42 4 3.74
1995 0.640 2 2.04
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票